2024-12-25 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**1. Performance Comparison & Overview:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  The cumulative return of MRK is 64.58%, significantly lagging behind the S&P 500 (VOO) which has a cumulative return of 117.56%. The difference is -53.0%, placing it at the 9.5th percentile of its historical performance relative to the S&P 500 (based on provided data).  This indicates underperformance compared to the broader market.  The provided alpha consistently shows negative values suggesting underperformance relative to the market benchmark, while Beta fluctuates showing varying levels of market sensitivity.


**2. Recent Price Movement:**

* **Closing Price:** $99.37
* **Last Market Price:** $99.45
* **5-day Moving Average:** $99.07
* **20-day Moving Average:** $100.49
* **60-day Moving Average:** $102.84

The price is slightly below the 5-day and 20-day moving averages, suggesting a short-term downward trend, but significantly below the 60-day moving average, indicating a longer-term downtrend.


**3. Technical Indicators & Expected Return:**

* **RSI:** 45.04 (Slightly below the neutral level of 50, suggesting neither overbought nor oversold conditions.)
* **PPO:** -0.0745 (Negative value suggests bearish momentum.)
* **Recent Relative Divergence:** +2.7 (Short-term upward movement, but not necessarily a strong indication of sustained upward trend.)
* **Expected Return:** 0.0% (This suggests that over the long term (2+ years) with consistent investment, the expected return relative to the S&P 500 is neutral. However, this needs further analysis beyond the provided data.)

The Last Market price of 99.45 doesn't reflect any significant sudden price movements (no sharp up or downturns based solely on this data).


**4. Recent Earnings Analysis:**

The provided earnings data shows some inconsistencies (duplicate entry for 2024-11-06).  Focusing only on the unique entries and excluding duplicates, we can observe the following:

* **Revenue:** Revenue has generally increased quarter-over-quarter, but the trend isn't consistently strong.
* **EPS:** EPS fluctuates; no clear upward or downward trend is easily discernible from this limited data.  More data is needed for a strong conclusion.  There's a significant drop from Q2 2024 to Q3 2024 EPS.
* **Notable Beats/Misses:**  Without expectations data, we cannot determine whether any quarters "beat" or "missed" expectations.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue shows growth, albeit not consistently strong. Profit margins are generally high but have shown some slight recent decreases.
* **Capital and Profitability:** Equity has generally increased.  ROE shows significant fluctuation, including a negative value in Q4 2023, indicating a period of loss.


**6. News and Recent Issues:**

* **No recent earnings news is included** in the provided information to cover the last 2 days.
* **Market Outlook and Analyst Opinions:** Not provided in the given data.


**7. Overall Analysis:**

Merck (MRK) shows mixed signals. While revenue is generally increasing and profit margins remain high,  the stock's performance significantly lags behind the S&P 500.  Recent earnings show volatility in EPS, and technical indicators suggest a slightly bearish short-term outlook. The long-term outlook is unclear without more comprehensive analysis and information on market expectations and future projections.  The provided expected return of 0% relative to the S&P 500 warrants further investigation.  More data, particularly concerning analyst expectations and future projections, is needed for a more conclusive assessment.  The inconsistency in the reported earnings data needs clarification.


**8. Disclaimer:** This report is based solely on the limited data provided. It is not financial advice, and independent research and consultation with a financial professional are recommended before making any investment decisions.
